Sunshine Biopharma Files 8-K on Financials
Ticker: SBFMW · Form: 8-K · Filed: Aug 19, 2024 · CIK: 1402328
| Field | Detail |
|---|---|
| Company | Sunshine Biopharma, Inc (SBFMW) |
| Form Type | 8-K |
| Filed Date | Aug 19, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
Related Tickers: SBFM
TL;DR
Sunshine Biopharma dropped an 8-K on financials, check it out.
AI Summary
Sunshine Biopharma, Inc. filed an 8-K on August 19, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located at 333 Las Olas Way, Fort Lauderdale, FL.
Why It Matters
This filing provides investors with an update on Sunshine Biopharma's financial performance and condition, which is crucial for assessing the company's health and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial reporting filing and does not contain information that inherently increases risk.
Key Players & Entities
- Sunshine Biopharma, Inc. (company) — Registrant
- August 19, 2024 (date) — Date of earliest event reported
- 333 Las Olas Way, Fort Lauderdale, FL (location) — Principal executive offices
- Colorado (jurisdiction) — State of incorporation
- 001-41282 (identifier) — Commission File Number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Sunshine Biopharma, Inc.'s Results of Operations and Financial Condition, and to include Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on August 19, 2024.
Where are Sunshine Biopharma, Inc.'s principal executive offices located?
Sunshine Biopharma, Inc.'s principal executive offices are located at 333 Las Olas Way, CU4 Suite 433, Fort Lauderdale, FL 33301.
In which state was Sunshine Biopharma, Inc. incorporated?
Sunshine Biopharma, Inc. was incorporated in Colorado.
What is the Commission File Number for Sunshine Biopharma, Inc.?
The Commission File Number for Sunshine Biopharma, Inc. is 001-41282.
Filing Stats: 525 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2024-08-19 16:05:35
Key Financial Figures
- $0.001 — ch Registered Common Stock, par value $0.001 SBFM The Nasdaq Stock Market LLC
Filing Documents
- sunshine_8k.htm (8-K) — 28KB
- sunshine_ex9901.htm (EX-99.1) — 18KB
- image_001.jpg (GRAPHIC) — 6KB
- 0001683168-24-005903.txt ( ) — 271KB
- sbfm-20240819.xsd (EX-101.SCH) — 3KB
- sbfm-20240819_def.xml (EX-101.DEF) — 26KB
- sbfm-20240819_lab.xml (EX-101.LAB) — 36KB
- sbfm-20240819_pre.xml (EX-101.PRE) — 25KB
- sunshine_8k_htm.xml (XML) — 5KB
02 Results of Operations and Financial
Item 2.02 Results of Operations and Financial Condition. On August 19, 2024, Sunshine Biopharma, Inc. (the "Company") issued a press release announcing the Company's financial results for the period ended June 30, 2024. The press release is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release 104 Cover Page Interactive Data File (formatted in Inline XBRL). 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: August 19, 2024 SUNSHINE BIOPHARMA, INC. By: /s/ Dr. Steve N. Slilaty Dr. Steve N. Slilaty, Chief Executive Officer 3